REF investigators gather to share research progress and trade advice
How Energy Shifts Lead to Systemic Illness
The impact of adaptive energy programs on the manifestations of chronic inflammatory disease
RA Treatment May Be Beneficial Even After Patients Meet Remission Criteria
An analysis of wrist MRIs from participants in the Treatment of Early Aggressive Rheumatoid Arthritis (TEAR) clinical trial indicates that patients continue to show joint inflammation even after two years of early aggressive therapy.
Treat Rheumatoid Arthritis to Target
The time has come for goal-directed management of RA
Could Lipids Be a Key to Control Inflammation?
Presenters spotlight complex relationship between lipid metabolism, atherosclerosis, and autoimmune disorders
BATTER-UP Takes Swing at Potential RA Biomarkers
Ongoing study aims to identify patients unlikely to respond to anti-TNF drugs
New Criteria for RA Remission
ACR and EULAR update 1981 criteria to reflect modern treatment options
Expression of CD154 Protein Linked to Increased Risk for Developing RA
An ongoing study of key immune system proteins has pinpointed an area associated with increased risk for inflammatory disease and may one day lead to new therapies to control inflammation and rheumatic diseases.
Chronotherapy with Glucorticoids in Rheumatoid Arthritis
Time is of the essence in balancing risks and benefits
Naturally Occurring Antibodies May Lead to New RA Therapies
A study published in the Journal of Immunology indicates that naturally occurring antibodies in the human immune system have the capacity to suppress inflammatory responses throughout the body. These antibodies may provide researchers an opportunity to develop new therapies for rheumatoid arthritis (RA) and other inflammatory conditions using similar pathways.
- « Previous Page
- 1
- …
- 64
- 65
- 66
- 67
- 68
- …
- 74
- Next Page »